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ABSTRACT
Introduction. This study was conducted on a population of patients with inflammatory bowel disease (IBD) 
and was based on an assessment of the prevalence and severity of depression and anxiety symptoms in 
various clinical aspects. The psychological features of IBD patients are very important in the perception of 
symptoms, but crucial as triggers of IBD or as a releasing factor for IBD symptoms recurrence. 
Methods. The study included 130 patients with IBD, including 68 with Crohn’s disease (CD) and 62 with 
ulcerative colitis (UC). The severity of anxiety and depression symptoms were examined by the Hospital 
Anxiety and Depression Scale (HADS). Patients were also subjected to assessment of anthropometric 
attributes, clinical factors, quality of life, and symptoms of the disease, with dedicated clinical scales.
Results. The occurrence of significant symptoms of anxiety was estimated at 45.5% in patients with CD 
and 30.5% in the UC patients. Significant depressive symptoms related to 20.5% of people with CD and 
17.5% of patients with UC. The parameters of anxiety and depression showed significant associations with 
parameters of quality of life, BMI, and the scales describing the exacerbation of the diseases. 
Conclusions. The analyses did not reveal significant differences in the severity and prevalence of symptoms 
of anxiety and depression in subgroups with IBD. The expansion of relevant symptoms of anxiety and 
depression in this population was greater than in the general population. In addition, there was a significant 
correlation between parameters of HADS and clinical factors. 
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Introduction
The prevalence of the inflammatory bowel diseas-
es (IBD) in adult Europeans is high; it reaches nearly 
140/100,000 people [1]. It is a group of chronic and 
recurrent diseases, comprised of Crohn’s disease (CD) 
and ulcerative colitis (CU). Both of these conditions 
are characterised by the occurrence of phases, with 
periods of remission and relapse. Genetic, environ-
mental, immunological, and psychosocial factors have 
an impact on the course and progression of IBD [2, 3]. 
The symptoms of IBD, as well as their complications 
(which are often numerous and serious), impair the lives 
of the patients in a severe way, lowering their quality of 
life [4–6]. The abovementioned is associated with the 
occurrence of depressive symptoms and anxiety in this 
group of patients [7].
Crohn’s disease can have clinical onset at any age; 
however, it starts mostly in the second or third decade 
of life. In 25% of cases the diagnosis is made before the 
age of 18 years [8]. The estimated prevalence of CD is 
12.7 cases per 100,000 people in Europe [9], and it has 
similar prevalence in women and men [1]. The disease 
can affect any part of the gastrointestinal tract, from the 
oral cavity to the anus. It is first located in the mucosa, 
and it spreads to the rest of the intestinal wall afterwards, 
which may cause many complications (narrowings, 
fistulas, abscesses). Affected segments are separated 
by healthy fragments of the gastrointestinal tract.
Ulcerative colitis is more frequent in Europe than CD 
(24.3 cases per 100,000 people) [9]. The disease may 
occur at any age; there are two peaks in incidence rates: 
between the age 15 and 30 years as well as (smaller) 
50 and 70 years [10, 11]. Unlike CD, it affects only the 
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mucosa and is restricted to the large intestine; it spreads 
continuously from the anus in the proximal direction.
Depression is the disease most often co-existing 
with IBD [12]. The higher prevalence of depressive 
symptoms in the group of CU patients was shown 
(24%) as opposed to CD patients (15%) [7]. Relevant 
differences were found in the prevalence and severity 
of depressive symptoms depending on the phase of the 
disease [13]. In patients without any earlier psychologi-
cal disorders, the risk factors of developing depression 
in the future were: female sex, aggressive course of the 
disease, and advanced endoscopic activity [14]. In the 
population of IBD patients who were over 65 years old, 
the risk factors were: lower education, treatment with 
corticosteroids, and lower physical activity; depression 
was associated with worse cooperation in treatment 
[15]. The sustainability of IBD symptoms despite 
treatment was likewise a risk factor for development of 
depression [12].
In CD, the risk of depression is higher when there is 
intense activity of the disease and low socioeconomic 
status. Older age and experiencing stress were ob-
served to be correlated with depression [16]. During 
a 5-year observation of over a thousand patients after 
a surgical procedure (707 patients with CD and 530 with 
CU) it was found that in the case of CD there is higher 
(around 16%) risk of depression than in CU. In CD, risk 
factors were: female sex, surgery in the first 3 years 
from the diagnosis, other concomitant diseases, immu-
nosuppressive drugs, ostomy and active inflammatory 
process in the anal area [17]. The risk of depression 
was 44% when 4 of these factors were present.
The factors connected with CU which in the studies 
showed correlation with depressive symptoms were: 
experiencing stress, activity of the disease, and hos-
pitalisations [16]. Surgery in CU caused 11% risk of 
developing depressive symptoms in five years. Other 
significant factors were female sex and other co-existing 
diseases [17].
The anxiety symptoms among patients with IBD 
are two times more frequent than in the general pop-
ulation [18]. In this group, the factors that correlated 
most with anxiety were: chronic pain, female sex, and 
childhood sexual abuse [18]. Wider prevalence was 
observed during clinical exacerbation of IBD (80%) in 
comparison to remission (29%) [19]. It is thought that 
the main factors responsible for anxiety symptoms in 
the IBD population are: the awareness of incurability, 
the fear of surgical intervention, and the fear of neo-
plasm development [20]. It was likewise observed 
that religious patients experience lesser intensity of 
anxiety symptoms.
In regard to Crohn’s disease, Goodhand et al. found 
that experiencing stress, abdominal pain, and low socio-
economic status have an influence on the advancement 
of anxiety symptoms [16].
In the course of ulcerative colitis, the anxiety 
symptoms were more frequent in groups of patients 
suffering from stress and in those who were recently 
diagnosed [16].
As mentioned, there is clear evidence that in IBD 
the anxiety and depressive symptoms occur frequently. 
Their prevalence has been reported to be as high as 
80% and 60%, respectively, during relapses [21] and 
in up to 35% of patients in the remission state [22, 23]. 
The anxiety and depressive symptoms are likewise 
the main psychological factors influencing the clinical 
course of IBD [24]. Hence, the aim of this study was to 
evaluate the appearance and progression of anxiety and 
depressive symptoms within individuals with different 
activity of the disease. 
Materials and methods
The study involved 130 patients: 68 with CD 
(29 women and 38 men) and 62 with CU (29 women 
and 32 men). They were of Polish nationality and Cau-
casian ethnicity. Patients were treated on an outpatient 
basis. During the observation, the diagnosis did not 
change. Demographic factors are shown in Table 1.
Permission for the study was obtained from the Bio-
ethical Commission of Nicolaus Copernicus University, 
Collegium Medicum in Bydgoszcz. The subjects demon-
strated their willingness to participate in the project by 
signing an Informed Consent Form. All the patients 
were informed about the goal and process of the study, 
potential risks, anonymity of the data, and the possibility 
of cancelling their participation at any moment.
Assessments
The procedure of examination shown below was 
conducted once and consisted of clinical, biochemical, 
and psychological assessment.
Clinical assessment consisted of obtaining a med-
ical history, performing a physical examination, and 
filling out a questionnaire concerning the course of the 
disease and individual factors. 
The following types of parameters were assessed:
 — demographic (age, sex, education, place of resi-
dence, etc.);
 — relating to illness (disease type, duration, other 
diseases, risk factors of IBD or exacerbations, an-
thropometric parameters, etc.).
Anthropometric assessment: weight, height, and 
BMI (Body Mass Index) were obtained.
Scales describing the activity and course of the dis-
ease – scales used in everyday practice for monitoring 
patients were used:
 — for CD patients:
•	 CDAI (Crohn’s Disease Activity Index),
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 — for CU patients:
•	 Mayo Classification (The Mayo Score).
Quality of life was examined with the dedicated 
questionnaire — IBDQ (Inflammatory Bowel Disease 
Questionnaire). The IBDQ was used under license 
of McMaster University (Order # 29620 and Order 
#29621).
Psychological assessment applied mostly to the 
details of intensification of the depressive symptoms 
and anxiety, which were assessed using the HADS scale 
(Hospital Anxiety and Depression Scale).
Statistical analysis
STATISTICA 12.5 was used for statistical analyses; 
it was conducted for two groups. 
The distribution of variables was analysed using 
the Shapiro-Wilk test. To assess the significance of the 
differences between groups, the Mann-Whitney U test 
was used. The R-Spearman test was used to determine 
correlations between non-parametrical variables. Signif-
icant differences were assumed for p < 0.05.
Results
Subjects and baseline characteristics
Of the 130 patients who were invited to participate 
the study, 68 had a diagnosis of CD and 62 had a di-
agnosis of CU. There were no significant differences 
Table 1. Basic demographic and clinical parameters in subgroups of patients with Crohn’s disease (CD) and 
ulcerative colitis (CU)
Parameter CD (n = 68) CU (n = 62) p
Age (y) 28.5 (22.0–36.5) 31.0 (21.0–50.0) 0.41





Duration of illness (y) 5.0 (3.0–8.0) 6.0 (2.0–8.0) 0.74
Education
Basic (n, %) 4 (6%) 4 (6.5%) 0.82
Vocational (n, %) 11 (16%) 8 (13%)
Secondary (n, %) 33 (48.5%) 31 (50%)
Higher (n, %) 20 (29.5%) 19 (30.5%)
Physical activity
None (n, %) 25 (37%) 24 ( 39%) 0.60
< 1/week 8 (12%) 14 (22.5%)
2–3/week 31 (45.5%) 16 (26%)
> 3/week 4 (5.5%) 8 (12.5%)
BMI [kg/m2] 22.1 (19.2–24.8) 22.5 (20.2–26.3) 0.19
Waist [cm] 81.0 (76.0–89.0) 83.0 (76.0–90.0) 0.55
Nicotinism (n. %) 11 (16%) 14 (23%) 0.81
Data is presented as median (Q25–Q75) or number and percentage. BMI — body mass index
Table 2. HADS results in the study group
CD (n = 68) CU (n = 62) p
HADS_A 7.0 (5.0–9.0) 6.0 (4.0–9.0) 0.69
HADS_D 4.0 (2.0–7.0) 4.0 (2.0–7.0) 0.90
Female (n = 59) Male (n = 71) p
HADS_A 8.0 (5.0–10.0) 6.0 (4.0–8.0) 0.008
HADS_D 4.0 (2.0–7.0) 3.0 (2.0–7.0) 0.76
Data presented as median (Q25–Q75). CD — Crohn’s disease;  
CU — ulcerative colitis; HADS_A — Hospital Anxiety and Depression 
Scale, subscale of anxiety; HADS_D — Hospital Anxiety and Depres-
sion Scale, subscale of depression
 
in the demographic and clinical parameters between 
the CD and CU groups with regards to age, gender, 
duration of illness, education, physical activity, BMI, 
waist circumference, and nicotinism (Tab. 1). 
Anxiety and depressive symptoms  
in the studied population
In the whole group of IBD patients the median value 
for severity of anxiety symptoms reached 7.0 and the 
median value for severity of depression was 4.0. There 
was no difference between the CD and CU groups in 
HADS_D scores, while the CD group gained insignifi-
cantly higher HADS_A results (Tab. 2). However, signifi-
cantly higher results of HADS_A scale were observed in 
the group of women versus men (p = 0.008) (Tab. 2). 
The analysis of the correlations between HADS_A and 
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Table 3. Spearman rank correlations of Hospital Anxiety and Depression Scale (HADS) subscales results with clinical 
parameters
Parameter HADS_A P HADS_D P
Age (y) 0.137002 0.14 0.294311 0.0007
Duration of illness (y) 0.045748 0.65 –0.059304 0.57
BMI –0.080805 0.36 0.211421 0.016
HADS_A — Hospital Anxiety and Depression Scale, subscale of anxiety; HADS_D — Hospital Anxiety and Depression Scale, subscale of depres-
sion; BMI — body mass index
Table 4. Results of Hospital Anxiety and Depression 
Scale (HADS) in subgroups of patients with Crohn’s 




CD (n = 17) CD (n = 51)
HADS_A 5.0 (0.0–8.0) 8.0 (1.0–19.0) 0.001
HADS_D 2.0 (0.0–9.0) 5.0 (0.0–16.0) 0.07
CU (n = 20) CU (n = 42) p
HADS_A 2.0 (0.0–8.0) 5.0 (0.0–13.0) 0.5
HADS_D 5.0 (0.0–12.0) 6.0 (0.0–16.0) 0.019
Data presented as median (Q25–Q75)
Table 5. The Inflammatory Bowel Disease Questionnaire (IBDQ) results and clinical parameters in groups with and 
without clinically significant symptoms of anxiety
Parameter HADS_A > 7 (n = 50) HADS_A ≤ 7 (n = 80) p
Age (y) 31.0 (22.0–46.0) 27.0 (20.0–39.0) 0.30
Gender ♀ 28 (56%)
♂ 22 (44%)
♀ 31 (39%)
♂ 49 (61%) 0.018
Duration of illness (y) 5.0 (3.0–8.0) 5.0 (2.0–8.0) 0.82
BMI 21.3 (18.9–24.1) 22.5 (20.4–25.8) 0.14
IBDQ (total) 154.5 (131–177) 173 (151–200) 0.0002
IBDQ emotional function 47 (39–54) 55 (46.5–62.0) 0.002
IBDQ bowel function 23.5 (17.5–28) 28 (24–32) 0.0004
IBDQ social function 57.5 (48.5–68) 66 (57.5–76.5) 0.0009
IBDQ systemic function 22.5 (19–27.5) 28 (24–31) 0.00009
Data presented as median (Q25–Q75) or number and percentage. BMI — body mass index; HADS_A — Hospital Anxiety and Depression Scale, 
subscale of anxiety
HADS_D results with clinical parameters revealed sta-
tistically significant positive association of depression 
subscale with age (r = 0.29; p = 0.0007) and BMI 
(r = 0.21; p = 0.01) (Tab. 3). Also, the group of patients 
with overweight achieved significantly higher median 
levels of depressive symptoms (6.0 vs. 3.5, p = 0.04).
The clinical CDAI scale for CD and Mayo for CU was 
used to determine the patients who met the criteria for 
exacerbation and those who met criteria for remission 
of the disease symptoms. In patients with CD, subjects 
with exacerbation had a significantly higher levels of 
anxiety symptoms (p = 0.001), while CU patients with 
exacerbation were characterised by significantly higher 
levels of depressive symptoms (p = 0.019) (Tab. 4). 
Anxiety symptoms and quality of life 
Fifty patients presented clinically significant anxiety 
symptoms (38% of the study group). There were no 
significant differences between this group and the other 
patients in terms of age, disease duration, and BMI. 
However, all IBDQ parameters were significantly worse 
in this group (Tab. 5).
Depressive symptoms and quality of life
A similar analysis was also performed for depressive 
symptoms. It was found that significant depressive 
symptoms occurred in 30 persons (23% of the study 
group). These patients did not differ from others in terms 
of gender and duration of illness. There was a difference 
in measure of tendency of BMI (24.1 vs. 21.8; p = 0.09). 
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Table 6. The Inflammatory Bowel Disease Questionnaire (IBDQ) results and clinical parameters in groups with and 
without clinically significant symptoms of depression
Parameter HADS_D > 7 (n = 30) HADS_D ≤ 7 (n = 100) p
Age (y) 39.0 (31.0–51.0) 26.0 (20.0–37.0) 0.0001





Duration of the illness (y) 6.0 (3.0–10.0) 5.0 (2.5–7.0) 0.33
BMI 24.1 (20.3–27.6) 21.8 (19.2–24.4) 0.09
IBDQ (total) 147 (132–163) 172 (146–199) 0.0005
IBDQ emotional function 47 (39–52) 53 (44–61) 0.003
IBDQ bowel function 23 (18–25) 28 (23–32) 0.0003
IBDQ social function 57 (49–63) 66 (57–76) 0.0004
IBDQ systemic function 22 (19–26) 28 (23–31) 0.0002
Data presented as median (Q25–Q75) or number and percentage. BMI — body mass index; HADS_D — Hospital Anxiety and Depression Scale, 
subscale of depression
As with anxiety symptoms, all aspects of quality of life 
measured by IBDQ were significantly lower in the group 
with HADS_D-positive results. 
Discussion
For many years clinicians and scientists have 
observed and described the psychological aspects in 
the group of patients who suffer from IBD. Relations 
between etiopathogenesis, clinical aspects of IBD, 
and psychological factors are still not well understood, 
despite the utilisation of more and more exact scientific 
methods. Such facets are very important consider-
ing the development of the disease and its course. 
In this study, we analysed the correlation between 
demographic, clinical, and biochemical factors and 
the occurrence and the intensity of depressive and 
anxiety symptoms.
Depressive and anxiety disorders are more fre-
quent in patients diagnosed with IBD than in the main 
population [12, 18]. The literature shows evidence 
of significant association between the activity of the 
disease and the occurrence of depressive symptoms 
and anxiety. Although depressive symptoms are more 
frequent in patients with CU, the anxiety disorders 
are slightly more common in individuals with CD. The 
data obtained in this study also confirm the existence 
of positive correlations between disease activity and 
symptoms of anxiety and depression.
In comparison to the literature, the prevalence 
of depressive symptoms was smaller in the experi-
mental group. Various publications describe patients 
in remission, whose depressive symptoms reach 
approximately 35% [22, 23]. In patients with exacer-
bation, significant depressive symptoms concern 60% 
of patients [21]. 
Practically all papers describing the relationship 
between the clinical course of IBD and depressive 
and anxiety symptoms show greater intensity during 
the course of the disease activity. A meta-analysis of 
30 studies from 1994 to 2014 indicates a significant 
correlation between the severity of IBD symptoms and 
the variety of psychological symptoms [25]. It is very 
important that there are significant differences in the 
prevalence and severity of depressive disorders de-
pending on the disease phase [19]. Thus, in the course 
of exacerbation, the prevalence of significant depressive 
symptoms was 60% [21]. By contrast, in the remission 
phase this was approximately 35% [22, 23].
The literature is dominated by publications in which 
excessive body weight is associated with a tendency 
to exacerbate depressive and anxiety symptoms. The 
cause of this phenomenon is seen in the inflammatory 
system that is modulated by obesity [26]. It was found 
that in a group of 10,348 women, BMI was positively 
correlated with mild to moderate depressive disorders 
and also with high levels of depression. It has also been 
reported that the degree of obesity was an independent 
risk factor for the occurrence of depressive disorders 
also in the population of obese women. Abdominal obe-
sity independently correlated positively with depressive 
symptoms [27]. Population studies in Canada have 
shown that in obese people mood disorders occurred 
two times more frequently than in healthy populations 
and 30% more often than in overweight populations [28]. 
In recent epidemiological studies, the incidence of 
obesity or overweight among IBD patients is estimated 
at 15–40%, and their occurrence significantly compli-
cates treatment, particularly the effectiveness of surgical 
intervention [29]. It is believed that IBD and obesity have 
many common elements, including intestinal microbio-
ta, diet, and proinflammatory features of intra-abdominal 
adipose tissue [30].
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In this study, the incidence of obesity was not 
associated with a significantly higher level of anxiety, 
whereas patients with obesity were significantly more 
depressed. To conclude, individuals with a clinically 
significant burden of malnutrition do not have higher 
levels of anxiety and depression.
The literature includes observations describing 
a decrease in quality of life in IBD patients, which is 
significantly greater in the CD subgroup [31]. There are 
also studies that show no differences in the quality of 
life in subgroups with different IBD [32]. Such discrep-
ancies may result from complications more commonly 
appearing in CD patients, for instance intestinal and 
parenteral disease [31]. Likewise, the specific quality 
of life assessment method utilised in particular studies 
might be responsible for inconsistent findings. 
In our study, the occurrence of significant depressive 
and anxiety symptoms correlated with poorer IBDQ 
scores. During their daily living, IBD patients have to 
face a variety of issues and challenges related to height-
ened levels of psychological distress. It includes low 
self-esteem, the feeling of being stigmatised, or distur-
bances in employment and relationships [25]. Likewise, 
the deterioration of the disease, which results from the 
elevated inflammatory response, related to both anxiety 
and depression, may account for the poorer outcome 
of quality of life questionnaires [26].
Conclusions
This study showed a high prevalence of depression 
and anxiety in the group of patients with IBD. According to 
our results, one fifth of patients with CD and one in six with 
CU presented depressive symptoms. Nearly half of CD 
patients and one third of individuals with CU demonstrated 
significant anxiety symptoms. In regard to gender, women 
manifested anxiety symptoms more often than men. 
Our study also showed that higher severity of 
depressive and anxiety symptoms is associated with 
greater clinical disease activity and worse quality of life 
scores. Moreover, the intensity of depressive symptoms 
was increased in the individuals who presented higher 
BMI values and hence were more obese. 
This study proves that psychiatric disorders are very 
common in IBD patients and have a detrimental impact 
in the course of the disease. Therefore, it is considerable 
to take mental health into consideration when making 
the decisions about planning treatment in patients who 
suffer from IBD. 
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